Latent Labs and AWS announce collaboration to scale generative AI for the Life Sciences

LONDON & SAN FRANCISCO, May 6, 2025 — Latent Labs, the company building AI foundation models to make biology programmable, today announced its multi-year collaboration with Amazon Web Services (AWS) to put AI directly in the hands of biologists, pharma, and biotech innovators around the world.

The AWS collaboration furthers Latent Labs’ mission to build frontier AI models for biology and empower scientists in their pursuit of innovative therapeutics. With AWS as one of their channels, Latent Labs can scale their reach to the scientific community and streamline access to their technology and services.

AWS is Latent Labs’ preferred cloud provider, providing the London & San Francisco based company with advanced AI training and inference capabilities. Latent Labs was also notably one of the AWS selected startups  for the 2024 AWS Generative AI Accelerator.

“Our goal is to democratize access to leading generative AI tools to help our life sciences customers discover and develop breakthrough therapies,” said Dan Sheeran, General Manager, Healthcare and Life Sciences, AWS. “We see an incredible opportunity for AI to fundamentally change drug discovery, and look forward to supporting scientists with Latent’s cutting edge tools.”

Simon Kohl, CEO and founder of Latent Labs, said “AWS is an ideal partner to scale and distribute our generative AI technologies. Accelerating and elevating research at scale is at the core of our mission, and we couldn’t be more excited about the collaboration.”

Latent Labs was founded by Simon Kohl, alumnus of DeepMind’s Nobel Prize-winning AlphaFold 2 team. The wider team brings together the very best minds in generative AI, engineering and biology with a rich heritage in experience from DeepMind, Microsoft, Google, Stability AI, Exscientia, Mammoth Bio, Altos Labs and Zymergen.

To register interest in Latent Labs tools get in touch via contact@latentlabs.com.